Dear All (wonkish but stick with it … I’m going to try very hard to de-wonk it; addendum: see also the follow-up newsletters, most recently on 22 Dec 2025), In an absolutely terrifying paper and technical report in today’s issue of Science, we are introduced in detail to the concept of “mirror” bacteria in which
Dear All, I’ve written before about the Vivli AMR Surveillance Data Challenge that seeks creative ways to reuse MICs from surveillance datasets (the 24 April 2023 newsletter covered the 2023 Challenge; the 15 June 2024 newsletter flagged the 2024 Challenge). As a reminder, Vivli is a clinical data sharing platform that was created in 2013 from a
Dear All, Just released, the 2026 NIAID DMID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks applications for projects to treat, prevent, and diagnose bacterial, fungal, and viral infections. Of interest for this community, the BAA’s Research Area 001 seeks applications by 21 Feb 2025 for bacterial and fungal projects across thee topics (see below my signature for
Dear All, Back in 2022, I wrote a newsletter about the World Health Organization putting out a call to form a Task Force of AMR Survivors. The Task Force of Antimicrobial Resistance Survivors was established last October and its members have been busy ever since! There are currently 12 members, each serving 2 years, and they
Dear All, I was delighted to learn today that NIAID has released RFA-AI-24-069, a notice of funding opportunity (NOFO) soliciting applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy R&D and advancing phage clinical research. Applications are due
Dear All (and with thanks to Patricia Bradford for leading on this newsletter), Did you know you can access raw datasets of antimicrobial susceptibility surveillance data that have been generated by the pharmaceutical industry? Indeed such datasets exist and we’d like to ensure everyone is aware of their availability and potential! Background: The 20 Oct
Dear All, The peri-UNGA week is generating a lot of activity! Having about a year ago launched a £30m fund for support of AMR innovation with a call for therapeutic projects (30 Oct 2023 newsletter; I am told that awards will be announced soon), PACE (Pathways to Antimicrobial Clinical Efficacy, a joint project of LifeArc,
Dear All, CARB-X have opened their 2nd funding round for 2024! The Expression of Interest (EoI) deadline is 4 Oct 2024, so time is short! The 2nd round has the same 4 basic areas as the first round (see 6 Mar 2024 newsletter for reference): Therapeutics for Infections Caused by Gram-Negative Pathogens (WHO and CDC
Dear All, Supplementing and augmenting their review of the clinical and preclinical pipeline through 31 Dec 2023 (see the 15 June 2024 newsletter for details), WHO have now released: A call for data on preclinical antibacterial projects Scope: Traditional and non-traditional antibacterial candidates covering the WHO bacterial priority pathogens as well as other resistant pathogens of public health
Dear All (with thanks to Kevin for leading on this newsletter and with a wonkish / long-read alert on this email … settle in for the ride!), Great news from TEAM UK! As of 12 August, the UK Subscription Program is no longer a pilot but is fully operational with an initial application deadline of